Pfizer's stock has recently struggled but remains a bargain with generous dividends. Is now a good time to invest in PFE?

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...

Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen acquisition. By 2030, Pfizer aims to add $25 billion to its top line. Pfizer has already boosted its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Federal investigators are investigating claims suggesting Pfizer delayed announcing test results of its Covid vaccine until after the 2020 presidential election, the Wall Street Journal reported ...

Pfizer has beaten Wall Street's revenue estimate ... including through the acquisition of Seagen and Biohaven Pharmaceuticals, which allowed it to rejuvenate its cancer and neuroscience franchises.

Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past couple ...

Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...